key: cord-0698325-c9k04et1
authors: Chourpiliadis, C.; Lovik, A.; Kahler, A. K.; Valdimarsdottir, U.; Frans, E. M.; Nyberg, F.; Sullivan, P. F.; Fang, F.
title: Short-term improvement of mental health after a COVID-19 vaccination
date: 2022-02-27
journal: nan
DOI: 10.1101/2022.02.22.22271327
sha: e30d0f4d0d7200f75b3ffd43a0ff7b9da0563c18
doc_id: 698325
cord_uid: c9k04et1

Abstract Importance: The role of COVID-19 vaccination on the mental health of the general population remains poorly understood. Objective: To assess the short-term change of depressive and anxiety symptoms in relation to COVID-19 vaccination among Swedish adults. Design: A prospective cohort study with monthly data collections on self-reported depressive and anxiety symptoms from December 2020 to October 2021 and COVID-19 vaccination from July to October 2021. Setting: The Omtanke2020 Study, Sweden. Participants: 7,925 participants of the Omtanke2020 study with complete data on depressive and anxiety symptoms and vaccination status. Intervention(s) or Exposure(s): Receiving the first or second dose of a COVID-19 vaccine. Main outcomes(s) and Measure(s): Binary measures of depression (PHQ-9, cut-off [≥] 10) and anxiety (GAD-7, cut-off [≥] 10) one month before the first dose, one month after the first dose, and, if applicable, one month after the second dose. For individuals not vaccinated or chose to not report vaccination status (unvaccinated individuals), we selected three monthly measures of PHQ-9 and GAD-7 with 2-month intervals in-between based on data availability. Results: 5,079 (64.1%) individuals received two doses of COVID-19 vaccine, 1,977 (24.9%) received one dose, 305 (3.9%) were not vaccinated, and 564 (7.1%) chose not to report vaccination status. There was a lower prevalence of depression and anxiety among vaccinated, compared with unvaccinated, individuals, especially after the second dose. Among individuals receiving two doses of vaccine, the prevalence of depression and anxiety was lower after both first (aRR=0.82, 95%CI 0.76-0.88 for depression; aRR=0.81, 95%CI 0.73-0.89 for anxiety) and second (aRR=0.79, 95%CI 0.73-0.85 for depression; aRR=0.73, 95%CI 0.66-0.81 for anxiety) dose, compared with before vaccination. Similar results were observed among individuals receiving only one dose (aRR=0.76, 95%CI 0.68-0.84 for depression; aRR=0.82, 95%CI 0.72-0.94 for anxiety, comparing after first dose to before vaccination). These results were independent of age, sex, recruitment type, body mass index, smoking, relationship status, history of psychiatric disorder, number of comorbidities, COVID-19 infection status, and seasonality. Conclusions and Relevance: We observed a positive short-term change in depressive and anxiety symptoms among adults receiving a COVID-19 vaccine in the current pandemic.

The COVID-19 pandemic has caused an unprecedented health crisis worldwide. The negative mental health impact of the pandemic has been demonstrated, affecting both the infected and non-infected individuals (1, 2) . Vaccination against COVID-19 has been suggested to have a beneficial impact on mental health, in addition to protection from severe infection (3) . However, the existing evidence rests on a restricted phase of the vaccine rollout (4) and studies with relatively small sample size (5) .

Our aim was to provide an estimate of the short-term change in mental health after the vaccination against COVID-19, specifically depression and anxiety, during a long phase of the vaccine rollout and using a large study sample with careful adjustment for the impact of age, sex, history of COVID-19 infection, etc. We hypothesized that receiving a COVID-19 vaccine was associated with a decrease in the prevalence of depressive and anxiety symptoms.

We performed a longitudinal study based on the Omtanke2020 study, an ongoing prospective cohort study specifically designed to assess the mental health impact of COVID-19 in Sweden (6) . Over 28,000 adult Swedish residents were recruited to Omtanke2020 between June 2020 and June 2021 and provided self-reported data on mental and physical health, sociodemographic factors, lifestyle factors, and COVID-19-specific questions such as infection and vaccination (6, 7) .

In the present study, we included all participants of Omtanke2020 with monthly data on depressive and anxiety symptoms between December 2020 and October 2021. These participants also had to have data on COVID-19 vaccination collected between 17 th July and 30 th October 2021. We excluded from the analysis 40 participants with inconsistent information on vaccination (e.g., time of the 2 nd dose preceding that of the 1 st dose) and 22 participants who received the 1-dose Janssen vaccine. We defined the vaccinated individuals as those reporting having received two doses or one dose of a COVID-19 vaccine, and the unvaccinated individuals as those reporting no vaccination or chose not to report vaccination status. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The Patient Health Questionnaire (PHQ-9) (8) was used to measure depressive symptoms whereas the Generalized Anxiety Disorder (GAD-7) (9) scale was used to measure anxiety symptoms. The binary outcomes of depression and anxiety were calculated from the total scores of these scales, which are shown to have appropriate psychometric properties in Omtanke2020 (6) . A cut-off of 10 in each scale was used to define significant depressive or anxiety symptoms, respectively (8, 9) .

For vaccinated individuals, we considered depression and anxiety at three timepoints: one month before 1 st dose (baseline), first month after the first dose, and, if applicable, first month after the second dose. For unvaccinated individuals, we randomly selected three timepoints with a 2-month interval in-between during the study period (i.e., baseline/Time 0, 2 months after baseline/Time 1, and 4 months after baseline/Time 2).

We first used Poisson regression to calculate prevalence ratio, comparing the prevalence of depression and anxiety between vaccinated and unvaccinated individuals, at baseline, after 1 st dose/Time 1, and after 2 nd dose/Time 2. To disentangle the seasonality effect from the vaccine effect, we performed a stratified analysis by calendar month. We first calculated crude prevalence ratio and then adjusted the analysis for age, sex, body mass index (BMI), recruitment type (self-recruitment or by invitation), relationship status, current smoking, number of comorbidities, history of psychiatric disorder, history of COVID-19 infection, and month of baseline survey.

We also used a Generalized Estimating Equations (GEE) model to assess the temporal change in the prevalence of depression and anxiety among vaccinated and unvaccinated individuals separately. In this analysis, we adjusted for age, sex, BMI, recruitment type, relationship status, current smoking, number of comorbidities, history of psychiatric disorder, history of COVID-19 infection, and month of baseline survey and used robust standard error to correct for the overestimated standard error of a log-Poisson model with binary outcome (10).

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 27, 2022. ; https://doi.org/10.1101/2022.02.22.22271327 doi: medRxiv preprint A total of 7,925 individuals, with a mean age of 52.6 (±15.4) years and 83% women, were included in the analysis, including 5,079 (64.09%) with two doses and 1,977 (24.95%) with one dose of COVID-19 vaccine, 305 (3.85%) not vaccinated, and 564 (7.12%) not reporting vaccination status (Table 1) .

Although there tended to be a lower prevalence of depression and anxiety among the vaccinated individuals, compared with the unvaccinated individuals, already at baseline, the difference became greater after the 2 nd dose among those with two doses of vaccine and after the 1 st dose among those with one dose of vaccine ( 

The present study demonstrated a short-term improvement in the prevalence of depression and anxiety after COVID-19 vaccination in a large sample of Swedish adults. The improvement was more pronounced after the second dose, compared with the first dose, and was independent of age, sex, history of COVID-19 infection,

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Our results are consistent with previous research suggesting a positive influence of COVID-19 vaccination on mental health (3) (4) (5) 11 ). The present study extends however the existing knowledge by addressing several methodological issues of previous studies, such as cross-sectional study design (5, 11 ), relatively small sample size (5) vaccination across the globe.

We found an immediate positive change in symptoms of depression and anxiety after receiving a COVID-19 vaccination among adults in the current pandemic. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted February 27, 2022. ; (1 st or 2 nd dose) to the prevalence before vaccine among vaccinated individuals, and comparing the prevalence of later time points to baseline among the unvaccinated individuals. Unvaccinated individuals include individuals reporting no vaccination or chose to not report vaccination status. The analyses were performed using GEE models and adjusted for age, sex, recruitment type, body mass index, relationship status, current smoking, number of comorbidities, history of psychiatric disorder, history of COVID-19 infection, and month of baseline survey All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 27, 2022. ; https://doi.org/10.1101/2022.02.22.22271327 doi: medRxiv preprint

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry

COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic

COVID-19 vaccines and mental distress

Does COVID-19 vaccination improve mental health? A difference-in-difference analysis of the Understanding Coronavirus in America study

Changes in Mental Health and Preventive Behaviors before and after COVID-19 Vaccination: A Propensity Score Matching (PSM) Study. Vaccines (Basel)

Mental health indicators in Sweden over a 12-month period during the COVID-19 pandemic

Cohort Profile: COVIDMENT: COVID-19 cohorts on mental health across six nations

The PHQ-9: validity of a brief depression severity measure

A brief measure for assessing generalized anxiety disorder